Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Daisuke Ogiya, MD PhD, Lisa Müller, Sigitas J Verselis, PhD, Heiner Schaal, PhD, Ivane Abiatari, MD, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Sophia Adamia, PhD

Blood (2019) 134 (Supplement_1): 1804.

https://doi.org/10.1182/blood-2019-131775

Published: 2019

Journal Articles

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Evangelos Terpos, MD PhD, Ramón García-Sanz, MD PhD, Kazuyuki Shimizu, MD, Wolfgang Willenbacher, MD PhD, Anthony Glennane, MD, Tian Dai, PhD, Walraud Pasteiner, PhD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 606.

https://doi.org/10.1182/blood-2019-127290

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Adam J Olszewski, MD, Peter Barth, MD, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 709.

https://doi.org/10.1182/blood-2018-99-110739

Published: 2018

Journal Articles

Evidence Based Recommendations for Supportive Care in Multiple Myeloma

Anum Qureshi, Muhammad Junaid Tariq, MD, Zunairah Shah, MBBS, Muhammad Abu Zar, MD, Shehroz Aslam, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Ahmad Kamal, MD, Jemin Aby Jose, MD, Insija Ilyas Selene, MBBS, Madeeha Shafqat, Faiza Jamil, MD, Seren Durer, MD, Ceren Durer, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2018-99-110748

Published: 2018

Journal Articles

Phase II Clinical Trial of Personalized-VCD-VTD Sequential Therapy Using VES-13 for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Tomonori Nakazato, MD PhD, Masao Hagihara, Seiji Irie, Naohi Sahara, Eri Tanaka, Yotaro Tamai, Ryuji Ishii, Shigehisa Tamaki, Atsushi Wake, MD PhD, Kenji Tajika, Rika Sakai, MD PhD, Takeshi Kobayashi, MD, Fumiya Sano, Takayuki Abe, Rachel Roberts, Shin Fujisawa, MD PhD, Koji Miyazaki, Masaaki Higashihara

Blood (2017) 130 (Supplement 1): 3162.

https://doi.org/10.1182/blood.V130.Suppl_1.3162.3162

Published: 2017

Journal Articles

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States

Leah J McGrath, PhD, Rohini K Hernandez, PhD, Robert Overman, PhD, Diane Reams, Pharm.D., MPH, Alexander Liede, MSc, PhD, M. Alan Brookhart, PhD

Blood (2017) 130 (Supplement 1): 534.

https://doi.org/10.1182/blood.V130.Suppl_1.534.534

Published: 2017

Journal Articles

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Sumita Bhatta, MD, Lori Cyprien, Rafael Fonseca, MD, Rohini K Hernandez, PhD, Christopher Kim, PhD

Blood (2017) 130 (Supplement 1): 2171.

https://doi.org/10.1182/blood.V130.Suppl_1.2171.2171

Published: 2017

Journal Articles

Statin Use and Its Effects on Skeletal Related Events in Patients with Multiple Myeloma

Fernando M Vargas Madueno, MD, Amin Benyounes, MD, Gentry King, MD, Kuan-Hsiang Gary Huang, MDPhD, Gabor Varadi, MD

Blood (2014) 124 (21): 5774.

https://doi.org/10.1182/blood.V124.21.5774.5774

Published: 2014

Journal Articles

Effects of Monoclonal Gammopathy of Undetermined Significance (MGUS) on Outcomes after Solid Organ Transplant

Teresa E Goebel, D.O., Nicholas K Schiltz, PhD, Aiswarya Chandran Pillai, MD/M.S., Paolo Caimi, MD, Siran M Koroukian, PhD, Kenneth J Woodside, MD, Erica L Campagnaro, MD

Blood (2014) 124 (21): 3507.

https://doi.org/10.1182/blood.V124.21.3507.3507

Published: 2014

Journal Articles

Frequency, Health Care Resource Use (HCRU), and Costs Associated With Skeletal Related Events (SREs) In US Patients With Multiple Myeloma (MM)

Emily Nash Smyth, PharmD, Ilaria Conti, MD, PhD, James Wooldridge, MD, Lee Bowman, PhD, Li Li, PhD, David Nelson, MS, Jin Xie, MS, Daniel E Ball, DrPH

Blood (2013) 122 (21): 2968.

https://doi.org/10.1182/blood.V122.21.2968.2968

Published: 2013

Journal Articles

Skeletal-Related Events In Myeloma: A Population-Based Study

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Bagguley Timothy, MSc, Alexandra Smith, PhD, Han-I Wang, PhD, Debra Howell, PhD, Hazem A Sayala, MBChB, MRCP, Gordon Cook, MD, PhD, Andrew Jack, PhD, Russell Patmore, MD, Eve Roman, PhD

Blood (2013) 122 (21): 3158.

https://doi.org/10.1182/blood.V122.21.3158.3158

Published: 2013

Journal Articles

Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment

Evangelos Terpos, Nikolaos Kanellias, Lia A Moulopoulos, Dimitrios Christoulas, Andreas Koureas, Tina Bagratuni, Vasilios Koutoulidis, Efstathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3090.

https://doi.org/10.1182/blood.V122.21.3090.3090

Published: 2013

Journal Articles

Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.

Ramón García-Sanz, Albert Oriol, Javier De La Rubia, MD, Luis Palomera, MD, Paz Ribas, Miguel Teodoro Hernández, Maria José Moreno, Joan Bargay, Angel Ramírez, Ana Isabel Teruel, María Jesús Blanchard, Mercedes Gironella, MD, Miquel Granell, MD, Eugenia Abella, J.F. San Miguel

Blood (2012) 120 (21): 2967.

https://doi.org/10.1182/blood.V120.21.2967.2967

Published: 2012

Journal Articles

Interaction of HGAL with Grb2 Enhances RhoA and B-Cell Receptor Signaling

Xiaoyu Jiang, PhD, Xiaoqing Lu, M.D, Izidore S Lossos, MD

Blood (2012) 120 (21): 681.

https://doi.org/10.1182/blood.V120.21.681.681

Published: 2012

Journal Articles

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Chirayu Patel, Andrew Yee, Tyler A. Scullen, Neeharika Nemani, Loredana Santo, Anuj Mahindra, Paul G. Richardson, MD, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Robert Schlossman, MD, Kenneth C. Anderson, Nikhil C Munshi, MD, Noopur Raje

Blood (2012) 120 (21): 3965.

https://doi.org/10.1182/blood.V120.21.3965.3965

Published: 2012

Journal Articles

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Lara Pochintesta, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Alessandra Pompa, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 4003.

https://doi.org/10.1182/blood.V120.21.4003.4003

Published: 2012

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

NARROW

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Evidence Based Recommendations for Supportive Care in Multiple Myeloma

Phase II Clinical Trial of Personalized-VCD-VTD Sequential Therapy Using VES-13 for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Statin Use and Its Effects on Skeletal Related Events in Patients with Multiple Myeloma

Effects of Monoclonal Gammopathy of Undetermined Significance (MGUS) on Outcomes after Solid Organ Transplant

Frequency, Health Care Resource Use (HCRU), and Costs Associated With Skeletal Related Events (SREs) In US Patients With Multiple Myeloma (MM)

Skeletal-Related Events In Myeloma: A Population-Based Study

Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment

Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.

Interaction of HGAL with Grb2 Enhances RhoA and B-Cell Receptor Signaling

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only